# Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis

**Authors:** Ji-yong Bae, Hyun-Kyung Sung, Na-Yoen Kwon, Ho-Yeon Go, Tae-jeong Kim, Seon-Mi Shin, Sangkwan Lee

PMC · DOI: 10.3390/medicina58010044 · Medicina · 2021-12-28

## TL;DR

This study reviews and analyzes the effectiveness of cognitive behavioral therapy in reducing migraine frequency and severity, finding it to be beneficial with few side effects.

## Contribution

A meta-analysis of randomized controlled trials evaluating the efficacy and safety of cognitive behavioral therapy for migraine treatment.

## Key findings

- CBT significantly reduced migraine frequency and MIDAS scores in the meta-analysis.
- Headache intensity was significantly reduced in subgroup analysis.
- Only a few adverse events were reported across the studies included.

## Abstract

Background and Objectives: Migraine headaches are chronic neurological diseases that reduce the quality of life by causing severe headaches and autonomic nervous system dysfunction, such as facial flushing, nasal stuffiness, and sweating. Their major treatment methods include medication and cognitive behavioral therapy (CBT). CBT has been used for pain treatment and various psychogenic neurological diseases by reducing pain, disability, and emotional disorders caused by symptoms of mental illness and improving the understanding of mental health. This study aimed to evaluate the effectiveness and safety of CBT in treating migraines. Materials and Methods: Seven electronic databases were searched from the date of inception to December 2020. Randomized controlled studies (RCTs) using CBT as an intervention for migraine were included. The primary outcome of this study was to determine the frequency of migraines and the intensity of migraines on Visual Analog Scale (VAS), the frequency of drug use, Migraine Disability Assessment (MIDAS), and Headache Impact Test (HIT-6) index. The two authors independently conducted the data extraction and quality assessment of the included RCTs, and conducted meta-analysis with RevMan V.5.4. Results: Among the 373 studies, 11 RCTs were included in this systematic review. Seven out of the 11 RCTs were conducted in the USA, and four were conducted in the UK, Germany, Iran, and Italy, respectively. Headache frequency and MIDAS scores were statistically significant reduced. In the subgroup analysis, headache strength was significantly reduced. Two of the included studies reported adverse effects, including worsening of migraine intensity and frequency, respiratory symptoms, and vivid memory of a traumatic event. Conclusions: CBT for migraine effectively reduced headache frequency and MIDAS score in meta-analysis and headache intensity subgroup analysis, with few adverse events. Additional RCTs with CBT for migraine headaches are needed for a more accurate analysis.

## Linked entities

- **Diseases:** migraine (MONDO:0005277)

## Full-text entities

- **Genes:** CREB3L1 (cAMP responsive element binding protein 3 like 1) [NCBI Gene 90993] {aka C16DELp11.2, DEL16p11.2, OASIS, OI16}
- **Diseases:** Significantpsychiatric disorder (MESH:D009358), psychological disorders (MESH:D000067073), pain and dysfunction (MESH:D013001), tension-type HA (MESH:D018781), facial flushing (MESH:D005483), Migraine headaches (MESH:D008881), personality disorders (MESH:D010554), photophobia (MESH:D020795), complex regional pain syndrome II (MESH:D002422), phonophobia (MESH:D012001), Headache Disorders (MESH:D020773), Headache (MESH:D006261), HIT-6 (MESH:D053632), medication overuse headache (MESH:D051271), chronic pain (MESH:D059350), fibromyalgia (MESH:D005356), orthostatic intolerance (MESH:D054971), migraine with or without aura (MESH:D020326), dizziness (MESH:D004244), nausea (MESH:D009325), eating (MESH:D001068), influenza (MESH:D007251), w/o aura (MESH:D004827), fatigue (MESH:D005221), disability (MESH:D009069), respiratory adverse (MESH:D012131), Pain (MESH:D010146), developmental delay or impairment (MESH:D002658), HA (MESH:C537629), neurological disease (MESH:D020271), neurological disorder (MESH:D009461), Generalized Anxiety Disorder (MESH:C000726808), Substance dependency (MESH:D019966), respiratory symptoms (MESH:D012818), pneumonia (MESH:D011014), Anxiety (MESH:D001007), sleep disorder (MESH:D012893), autonomic nervous system dysfunction (MESH:D001342), Overuse (MESH:D012090), nasal stuffiness (MESH:D009668), major depressive disorder (MESH:D003865), sleep apnea (MESH:D012891), vomiting (MESH:D014839), Insomnia (MESH:D007319), Depression (MESH:D003866), Psychiatric (MESH:D001523), Mental health condition (MESH:D000071069), traumatic (MESH:D014947), bipolar disorder (MESH:D001714), psychosis (MESH:D011618), episodic migraine':ti (MESH:D000072676), hypertension (MESH:D006973), traumatic event (MESH:D002318)
- **Chemicals:** barbiturates (MESH:D001463), pyridoxine (MESH:D011736), HCB (MESH:D006581), triptan (MESH:D014363), nortriptyline (MESH:D009661), folate (MESH:D005492), riboflavin (MESH:D012256), topiramate (MESH:D000077236), Amitriptyline (MESH:D000639), acetaminophen (MESH:D000082), tramadol (MESH:D014147), propanolol (MESH:D011433), C (MESH:D002244), cobalamin (MESH:D014805), caffeine (MESH:D002110), HWB (-), 13C (MESH:C000615229), flunarizine (MESH:D005444), painkillers (MESH:D008691), ibuprofen (MESH:D007052), alcohol (MESH:D000438), FU (MESH:D005472), vitamin D (MESH:D014807)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A 13 I

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8777662/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8777662/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC8777662/full.md

---
Source: https://tomesphere.com/paper/PMC8777662